Envista Holdings Corporation (NYSE:NVST) Receives $21.33 Average Target Price from Brokerages

Shares of Envista Holdings Corporation (NYSE:NVST) have been given an average recommendation of “Hold” by the fifteen brokerages that are presently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $21.3333.

A number of research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Envista from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Mizuho set a $19.00 target price on Envista in a research report on Monday, November 3rd. Stifel Nicolaus set a $25.00 price target on Envista in a report on Thursday, October 30th. Weiss Ratings reissued a “sell (d)” rating on shares of Envista in a research report on Monday. Finally, Morgan Stanley upped their price objective on shares of Envista from $16.00 to $17.00 and gave the stock an “equal weight” rating in a report on Friday, August 1st.

Institutional Investors Weigh In On Envista

Several large investors have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd grew its holdings in Envista by 16,711.1% during the third quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock valued at $31,000 after purchasing an additional 1,504 shares during the period. PharVision Advisers LLC purchased a new stake in Envista in the 3rd quarter worth about $307,000. XTX Topco Ltd lifted its holdings in Envista by 90.4% during the third quarter. XTX Topco Ltd now owns 81,347 shares of the company’s stock valued at $1,657,000 after purchasing an additional 38,628 shares during the last quarter. Virtus Advisers LLC bought a new stake in shares of Envista in the third quarter valued at approximately $205,000. Finally, Verition Fund Management LLC lifted its holdings in Envista by 15.9% during the 3rd quarter. Verition Fund Management LLC now owns 164,084 shares of the company’s stock worth $3,342,000 after purchasing an additional 22,566 shares in the last quarter.

Envista Trading Down 0.3%

NYSE NVST opened at $20.99 on Thursday. The business’s fifty day moving average is $20.10 and its 200 day moving average is $19.86. Envista has a twelve month low of $14.22 and a twelve month high of $22.68. The company has a market cap of $3.45 billion, a price-to-earnings ratio of 65.61, a price-to-earnings-growth ratio of 1.09 and a beta of 1.05. The company has a quick ratio of 2.08, a current ratio of 2.44 and a debt-to-equity ratio of 0.46.

Envista (NYSE:NVST) last posted its quarterly earnings data on Wednesday, October 29th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. Envista had a return on equity of 4.84% and a net margin of 2.11%.The business had revenue of $669.90 million during the quarter, compared to the consensus estimate of $639.49 million. During the same period in the prior year, the business posted $0.12 earnings per share. Envista’s quarterly revenue was up 11.5% on a year-over-year basis. As a group, sell-side analysts expect that Envista will post 1 EPS for the current fiscal year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.